A phase IB study of ipilimumab with peginterferon alfa-2b in patients with unresectable melanoma

BACKGROUND: Ipilimumab and peginterferon alfa-2b are established systemic treatment options for melanoma that have distinct mechanisms of action. Given the need for improved therapies for advanced melanoma, we conducted an open-label, single institution, phase Ib study to assess the safety and toler...

Descripción completa

Detalles Bibliográficos
Autores principales: Brohl, Andrew S., Khushalani, Nikhil I., Eroglu, Zeynep, Markowitz, Joseph, Thapa, Ram, Chen, Y. Ann, Kudchadkar, Ragini, Weber, Jeffrey S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2016
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170897/
https://www.ncbi.nlm.nih.gov/pubmed/28031816
http://dx.doi.org/10.1186/s40425-016-0194-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170897/
https://www.ncbi.nlm.nih.gov/pubmed/28031816
http://dx.doi.org/10.1186/s40425-016-0194-1

Ejemplares similares